Checkpoint Inhibitor denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Checkpoint Inhibitors as Experimental

Cigna's experimental or investigational denial for a checkpoint inhibitor most commonly occurs when the drug is prescribed for a tumor type or treatment line that Cigna's coverage policy has not yet recognized as established — even if the drug itself is FDA-approved for other indications. Cigna maintains its own evidence-review process and may classify a use as experimental based on internal criteria that lag behind current FDA approvals, NCCN guideline updates, or published clinical evidence. This type of denial is especially common for checkpoint inhibitors used in rare tumor types, earlier lines of therapy than those historically covered, or combination regimens.

## Why This Denial Is Appealable

An experimental denial is one of the most legally and clinically contestable denial types. Under ACA §2719, it is subject to independent external review by an accredited IRO with expertise in the relevant specialty. ERISA §503 guarantees a full-and-fair review. External review of experimental denials in oncology has a notably high reversal rate when the appeal is well-documented and supported by current guideline and FDA approval status. The external-review window is typically 4 months from a final internal denial, with an expedited pathway for urgent situations.

If the use is FDA-approved for the patient's indication, that is the strongest appeal argument. If it is off-label but supported by an authoritative clinical compendium (such as NCCN, DRUGDEX, or AHFS) or published peer-reviewed evidence, that is also a cognizable legal basis for coverage under many state insurance laws and plan documents.

## The Appeal Process

1. Confirm the exact FDA-approved indication(s) for the prescribed checkpoint inhibitor by reviewing the current prescribing label. 2. Determine whether the patient's tumor type and line of therapy fall within an approved indication. 3. If FDA-approved for this use: cite the label directly in the appeal and request the denial be reversed as inconsistent with regulatory approval. 4. If off-label: obtain the applicable oncology guideline organization's recommendation and any supporting published literature compiled by the treating oncologist. 5. File a written internal appeal; escalate to external review if denied.

## Documentation to Gather

• Pathology, molecular, and staging records: Complete documentation of tumor type, biomarker profile (such as relevant receptor or mutation status per the FDA label), and stage.
• FDA label excerpt: The indication section of the prescribing information applicable to this patient's diagnosis.
• Guideline and literature support: The treating oncologist's summary of relevant guideline recommendations and peer-reviewed evidence.
• Oncologist's medical-necessity letter: Directly addressing Cigna's experimental criteria and explaining why the evidence base supports coverage.

## Criteria-Mapping Structure

Obtain Cigna's Coverage Policy defining its experimental/investigational standard. For each element of that standard, provide a direct citation — from the FDA label, guideline document, or medical record — that refutes the experimental classification. Address the evidence-sufficiency standard Cigna applies and show how current published evidence meets or exceeds it.